Aji Bio-Pharma a leading provider of biopharmaceutical contract development and manufacturing services, and Gene Tools LLC announced a formal collaboration to broaden access to phosphorodiamidate morpholino oligomers (PMOs), a unique class of oligonucleotide therapeutics with significant potential for treating a broad range of genetic diseases, such as Duchenne muscular dystrophy (DMD). This partnership addresses a critical gap in the development pipeline by enabling purified PMO production at early research stages and seamlessly bridging to Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) manufacturing.
PMOs are structurally distinct oligonucleotides that require specialized manufacturing capabilities. Aji Bio-Pharma has built deep expertise in PMO production through its AJIPHASE liquid-phase technology, optimized for large-scale GLP and GMP manufacturing. However, early-stage research demands smaller, diverse PMO batches—a need Aji Bio-Pharma is meeting through this collaboration with Gene Tools LLC, a leader in providing solid phase small scale PMO synthesis for researchers worldwide.
Under the agreement, Gene Tools LLC will provide pre-purified PMO synthesis, while Aji Bio-Pharma will perform purification and quality control. This combination will enable clients to accelerate from early assay-level research to toxicology and GLP studies, creating a smooth path toward clinical development.
Read More: Clinical Trials for Duchenne (List of All Researches)
